Table 2: Demographic and clinical characteristics of participants.
ALN: axillary lymph node, AC: adriamycin-cyclophosphamide, DTX: docetaxel, PTX: paclitaxel, CMF: cyclophospha midemethotrexate 5-fluorouracil, HER: trastuzumab.
| Characteristics | | N(%)(n=32) |
| Gender | Females | 32(100 %) |
| Age, year | 30–39 | 1(3.2 %) |
| 40–49 | 9(28.1%) |
| 50–59 | 9(28.1%) |
| 60–69 | 9(28.1%) |
| 70–79 | 3(9.3) |
| ≥80 | 1(3.2 %) |
| Job status | Not employed | 20(62.5 %) |
| Part-time job | 10(31.3 %) |
| Full-time job | 2(6.2 %) |
| BMI, kg/m2 | <22 | 7(21.9 %) |
| 22–25 | 7(21.9 %) |
| ≥25 | 18(56.2%) |
| Living conditions | Living with family | 21(65.6 %) |
| Living alone | 11(34.4 %) |
| Stage | IIA | 9(28.1%) |
| IIB | 7(21.9%) |
| IIIA | 12(37.5%) |
| ≥IIIB | 4(12.5%) |
| Operation Method | Breast-conserving surgery | 24(75.0 %) |
| Mastectomy | 8(25.0%) |
| ALNs dissection | Yes | 7(21.9%) |
| No | 25(78.1 %) |
| Time since surgery, year (median, interquartile range) | 1.7(1.2–2.7) |
| Hormonal therapy | Yes(received ratio) | 15(46.9%) |
| Radiotherapy | Yes(received ratio) | 19(59.4 %) |
| Chemotherapy | Yes(received ratio) | 32(100 %) |
| AC | 9(28.1 %) |
| DTX | 8(25.0%) |
| PTX | 7(21.9 %) |
| CMF | 6(18.8 %) |
| PTX+HER | 2(6.2 %) |